SCHEMBL974235

SCHEMBL974235

CNC(CCO)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.51
TRPA1 O75762 1/20 0.48
HTR2A P28223 3/20 0.45
HRH1 P35367 2/20 0.45
PRKACA P17612 1/20 0.44
CDK8 P49336 1/20 0.44
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44
PRKX P51817 1/20 0.44
PRKCQ Q04759 1/20 0.44
ROCK1 Q13464 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
CHRM2 P08172 1/20 0.44
ADRA1A P35348 1/20 0.44
RGS12 O14924 1/20 0.44
GLA P06280 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6825365 1.00 ALDH1A1 (0.51) ALDH1A1TRPA1HTR2AHRH1PRKACA
SCHEMBL8722488 1.00 ALDH1A1 (0.51) ALDH1A1TRPA1HTR2AHRH1PRKACA
Hydrochloric Acid SCHEMBL11398988 0.98 ALDH1A1 (0.50) ALDH1A1TRPA1HTR2AHRH1PRKACA
SCHEMBL1964722 0.83 ALDH1A1 (0.55) ALDH1A1TRPA1HTR2AHRH1PRKACA
SCHEMBL1964723 0.83 ALDH1A1 (0.55) ALDH1A1TRPA1HTR2AHRH1PRKACA
SCHEMBL4110424 0.83 ALDH1A1 (0.55) ALDH1A1TRPA1HTR2AHRH1PRKACA
SCHEMBL15787637 0.82 ALDH1A1 (0.41) ALDH1A1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL15787291 0.82 ALDH1A1 (0.41) ALDH1A1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL172587 0.81 ALDH1A1 (0.49) ALDH1A1HTR2AHRH1CHRM2ADRA1A
SCHEMBL17864360 0.81 PRKACA (0.49) ALDH1A1TRPA1HTR2AHRH1PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110194719-A A kind of preparation method in R- (-)-levels Moses spit of fland 山东大学 2019-09-03 CN disclosed
CN-107630049-B The biological preparation method of ephedrine 武汉茵茂特生物技术有限公司 2018-09-21 CN disclosed
CN-107630049-B The biological preparation method of ephedrine 武汉茵茂特生物技术有限公司 2018-09-21 CN disclosed
CN-107630050-A The biological preparation method of pseudoephedrine 武汉茵茂特生物技术有限公司 2018-01-26 CN disclosed
CN-107630049-A The biological preparation method of ephedrine 武汉茵茂特生物技术有限公司 2018-01-26 CN disclosed
CN-107630049-A The biological preparation method of ephedrine 武汉茵茂特生物技术有限公司 2018-01-26 CN disclosed
EP-3016951-B1 TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-05-31 EP disclosed
US-20160152628-A1 TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-06-02 US disclosed
EP-2170848-B1 PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES ASTRAZENECA AB (SE) 2014-10-22 EP disclosed
WO-2014159251-A2 INHIBITING NEUROTRANSMITTER REUPTAKE MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2014-10-02 WO disclosed
EP-1165570-B9 NOVEL PHOSPHORUS-CONTAINING PRODRUGS METABASIS THERAPEUTICS INC (US) 2007-02-21 EP disclosed
EP-1724276-A1 Novel phosphorus-containing prodrugs Metabasis Therapeutics, Inc. (US) 2006-11-22 EP disclosed
EP-1165570-B1 NOVEL PHOSPHORUS-CONTAINING PRODRUGS METABASIS THERAPEUTICS INC (US) 2006-08-23 EP disclosed
EP-1634886-A2 Novel phosphorus-containing prodrug Metabasis Therapeutics, Inc. (US) 2006-03-15 EP disclosed
CN-1733779-A Novel phosphorus-containing prodrug METABASIS THERAPEUTICS INC (US) 2006-02-15 CN disclosed
WO-2005058892-A1 PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-06-30 WO disclosed
EP-1379492-A1 INHIBITOR OF MONOAMINE UPTAKE ELI LILLY AND COMPANY (US) 2004-01-14 EP disclosed
WO-2002070457-A1 INHIBITOR OF MONOAMINE UPTAKE ELI LILLY AND COMPANY (US) 2002-09-12 WO disclosed
US-5149821-A Process and intermediates for optically active 3-formyltetrahydropyrans PFIZER INC (US) 1992-09-22 US disclosed
EP-0391070-A1 Process for the preparation of N-methyl-3-(p-trifluoro-methylphenoxy)-3-phenyl-propylamine and their salts ORION-YHTYMÄ OY FERMION (FI) 1990-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152628-A1 TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS MYLK, MYLK2, ROCK1 ALDH1A1 3223/4885TRPA1 1445/4885HTR2A 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.